Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  1999-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/01.ATV.19.12.3025PMID 10591684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1alpha in HepG2 cells.

  1999cited by this paper
• Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia.

  1998cited by this paper
• Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines.

  1998cited by this paper
• An animal model to study local oxidation of LDL and its biological effects in the arterial wall.

  1998cited by this paper
• Nuclear factor-kappaB activity and arterial response to balloon injury.

  1997cited by this paper
• Nuclear factor-κB activity and arterial response to balloon injury

  1997cited by this paper
• Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.

  1997cited by this paper
• Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo.

  1997cited by this paper
• Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries.

  1996cited by this paper
• Human monocytes/macrophages release TNF-alpha in response to Ox-LDL.

  1996cited by this paper
• Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis.

  1996cited by this paper
• Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2.

  1996cited by this paper
• Human Monocytes/Macrophages Release TNF-α in Response to Ox-LDL

  1996cited by this paper
• Oxidized LDL induces transcription factor activator protein-1 but inhibits activation of nuclear factor-kappa B in human vascular smooth muscle cells.

  1995cited by this paper
• Oxidized LDL Induces Transcription Factor Activator Protein–1 but Inhibits Activation of Nuclear Factor–κB in Human Vascular Smooth Muscle Cells

  1995cited by this paper
• Lipid oxidation and inflammation-induced intimal fibrosis in coronary heart disease.

  1994cited by this paper
• Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls

  1994cited by this paper
• Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis.

  1994cited by this paper
• Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon.

  1993cited by this paper
• Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells.

  1993cited by this paper
• Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells.

  1993cited by this paper
• Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries.

  1993cited by this paper
• Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules.

  1993cited by this paper
• Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

  1992cited by this paper
• The role of lipid peroxidation and antioxidants in oxidative modification of LDL.

  1992cited by this paper
• Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation.

  1992cited by this paper
• Hypertriglyceridemia and regulation of fibrinolytic activity.

  1992cited by this paper
• Physiological mechanisms for metalloproteinase activation.

  1992cited by this paper
• Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.

  1992cited by this paper
• Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells.

  1992cited by this paper
• Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

  1991cited by this paper
• Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta.

  1991cited by this paper
• Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.

  1991cited by this paper
• Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

  1990cited by this paper
• Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937.

  1990cited by this paper
• Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.

  1990cited by this paper
• The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease

  1990cited by this paper
• Isolation and characterization of the rat plasminogen activator inhibitor-1 gene.

  1990cited by this paper
• Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein.

  1990cited by this paper
• Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.

  1989cited by this paper
• Low density lipoprotein undergoes oxidative modification in vivo.

  1989cited by this paper
• Plasminogen activator inhibitors.

  1987cited by this paper
• Production of Plasminogen Activators and Inhibitor by Serially Propagated Endothelial Cells from Adult Human Blood Vessels

  1987cited by this paper
• Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation

  1984cited by this paper
• Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins.

  1981cited by this paper
• Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man.

  1979cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Elevated soluble LOX-1 predicts risk of first-time myocardial infarction

  2023cites this paper
• High Levels of Soluble Lectinlike Oxidized Low‐Density Lipoprotein Receptor‐1 Are Associated With Carotid Plaque Inflammation and Increased Risk of Ischemic Stroke

  2019cites this paper
• Plasma stem cell factor levels are associated with risk of cardiovascular disease and death

  2017cites this paper
• Plasminogen Activator Inhibitor-1 is Regulated Through Dietary Fat Intake and Heritability: Studies in Twins

  2017cites this paper
• LDL in mesangial cells Biphasic regulation of plasminogen activator/inhibitor by

  2016cites this paper
• Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

  2014cites this paper
• Impact of Lysophosphatidylcholine on the Plasminogen Activator System in Cultured Vascular Smooth Muscle Cells

  2012cites this paper
• Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients

  2012cites this paper
• Cysteinyl leukotriene signaling through perinuclear CysLT1 receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression

  2012cites this paper
• Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome: Immunohistochemical analysis.

  2011cites this paper
• Molecular biology-based assessment of vitamin E-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling.

  2011cites this paper
• Involvement of NADPH oxidase in up-regulation of plasminogen activator inhibitor-1 and heat shock factor-1 in mouse embryo fibroblasts induced by oxidized LDL and in apolipoprotein E-deficient mice

  2011cites this paper
• Régulation de protéine C-réactive vasculaire dans le diabète de type 2

  2010cites this paper
• Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1.

  2009influential citation
• Lipid Mediators and Tissue Factor Expression

  2008cites this paper
• Proteomic analysis of secretory proteins and vesicles in vascular research

  2008cites this paper
• Plasminogen Activator Inhibitor-1 Activity and 4G/5G Polymorphism in Hemodialysis

  2008cites this paper
• PAI‐1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes

  2008cites this paper
• Proteomic Analysis of Secretory Proteins and Vesicles in Vascular Research

  2008cites this paper
• Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications

  2007influential citation
• Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

  2007cites this paper
• Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients.

  2007cites this paper
• Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.

  2006cites this paper
• Plasminogen Activator Inhibitor-1 Deficiency Has Renal Benefits but Some Adverse Systemic Consequences in Diabetic Mice

  2006cites this paper
• Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA

  2006cites this paper
• Cell biology and lipoproteins in atherosclerosis.

  2006cites this paper
• The proteome and secretome of human arterial smooth muscle cells

  2005cites this paper
• Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease

  2005influential citation
• Induction of PAI‐1 expression by tumor necrosis factor α in endothelial cells is mediated by its responsive element located in the 4G/5G site

  2005cites this paper
• Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-beta signaling in mesangial cells.

  2005cites this paper
• Molecular mechanisms of lipid‐induced insulin resistance in muscle, liver and vasculature

  2005cites this paper
• Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.

  2005cites this paper
• Endothelial injury in atherosclerosis: identification of mediators and attenuation of inflammation by adenoviral augmentation of elafin and SLPI

  2005cites this paper
• Las estatinas como antioxidantes

  2005cites this paper
• Oxidative Stress Activates the Plasminogen Activator Inhibitor Type 1 (PAI-1) Promoter through an AP-1 Response Element and Cooperates with Insulin for Additive Effects on PAI-1 Transcription*

  2004cites this paper
• PAI‐1 and vasculopathy: the debate continues

  2004cites this paper
• Atherosclerosis, Hypertension and Diabetes

  2003cites this paper
• Fibrinolysis in LPS-induced chronic airway disease.

  2003cites this paper
• Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants

  2003cites this paper
• Dyslipoproteinemia and Fibrinolysis

  2003cites this paper
• The renin-angiotensin system is involved in the production of plasminogen activator inhibitor type 1 by cultured endothelial cells in response to chylomicron remnants.

  2003cites this paper
• Coagulation and Fibrinolysis in Diabetes

  2002cites this paper
• Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque

  2002cites this paper
• A Forkhead/Winged Helix-related Transcription Factor Mediates Insulin-increased Plasminogen Activator Inhibitor-1 Gene Transcription*

  2002cites this paper
• Plasminogen activator inhibitor-1 and the kidney.

  2002cites this paper
• Cellular signalling by tissue factor and lipoproteins in the pathogenesis of atherosclerosis.

  2002cites this paper
• Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells.

  2002cites this paper
• Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain.

  2002cites this paper
• The expression of extracellular-superoxide dismutase is increased by lysophosphatidylcholine in human monocytic U937 cells.

  2002cites this paper
• Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1.

  2002cites this paper
• translational physiology Plasminogen activator inhibitor-1 and the kidney

  2002cites this paper
• Papel de los antioxidantes en la prevención de la enfermedad cardiovascular

  2001cites this paper
• [Role of antioxidants in the prevention of cardiovascular disease].

  2001cites this paper
• The stabilized plaque: will the dream come true?

  2001cites this paper
• Evidence for a role of phospholipid oxidation products in atherogenesis.

  2001cites this paper
• Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1.

  2001cites this paper
• The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflammatory transcription factors in primary human monocytes.

  2000cites this paper
• In Vivo Stimulation of Vascular Plasminogen Activator Inhibitor-1 Production by very Low-Density Lipoprotein Involves Transcription Factor Binding to a VLDL-Responsive Element

  2000cites this paper